Janux Therapeutics, Inc.
JANX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $10 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | $9 | $0 | $0 | $0 |
| % Margin | 95% | – | – | – |
| R&D Expenses | $35 | $35 | $25 | $21 |
| G&A Expenses | $0 | $10 | $10 | $8 |
| SG&A Expenses | $10 | $10 | $10 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $45 | $45 | $35 | $29 |
| Operating Income | -$35 | -$45 | -$35 | -$29 |
| % Margin | -352.5% | – | – | – |
| Other Income/Exp. Net | $11 | $11 | $11 | $9 |
| Pre-Tax Income | -$24 | -$34 | -$24 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24 | -$34 | -$24 | -$20 |
| % Margin | -243.1% | – | – | – |
| EPS | -0.39 | -0.55 | -0.38 | -0.36 |
| % Growth | 29.1% | -44.7% | -5.6% | – |
| EPS Diluted | -0.39 | -0.55 | -0.38 | -0.36 |
| Weighted Avg Shares Out | 62 | 62 | 62 | 57 |
| Weighted Avg Shares Out Dil | 62 | 62 | 62 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $11 | $11 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$24 | -$45 | -$34 | -$29 |
| % Margin | -238.1% | – | – | – |